

PRESS RELEASE

25 June 2025 14:30:00 CEST

Saniona highlights Acadia Pharmaceuticals' upcoming R&D Day

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its partner, Acadia Pharmaceuticals, is hosting a R&D Day today, where it will provide updates on its neurological and rare disease pipeline, including ACP-711 (formerly SAN711), a program originally developed by Saniona.

ACP-711 is a first-class, highly selective GABA A- α 3 positive allosteric modulator, which Saniona outlicensed to Acadia Pharmaceuticals in 2024 for the treatment of neurological diseases. Under the terms of the agreement, Saniona retains the right to receive development, regulatory, and commercial milestones, as well as tiered royalties on future net sales of ACP-711 that may result from its development.

"We are pleased to see ACP-711 progressing under Acadia's leadership and be part of their upcoming R&D Day. This compound represents a novel mechanism of action for the treatment of neurological disorders, and we look forward to Acadia's continued advancement of this promising program," said Thomas Feldthus, CEO of Saniona.

Acadia's R&D Day will be held on Wednesday, 25 June, 2025 at 8:30 AM ET in New York City. The event will feature presentations from Acadia's management, R&D leadership, key opinion leaders (KOLs), and members of the caregiver community. Registration for the live webcast is available here:

<https://lifescievents.com/event/acadia-webcast/>

For more information, please contact

Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases. Its internal pipeline includes SAN2219 and SAN2355 for epilepsy and SAN2465 for major depressive disorder. Saniona has two strategic collaborations: one with Acadia Pharmaceuticals, which has licensed worldwide rights to ACP-711 and is preparing it for Phase 2 in essential tremor, and one with Productos Medix, which holds the rights to tesofensine for obesity in Mexico and Argentina and has submitted a market authorization application in Mexico. Saniona also has two clinical programs available for partnership: Tesomet™, ready for Phase 2b in rare eating disorders, and SAN903, ready for Phase 1 in inflammatory bowel disease. Saniona's partners also include Boehringer Ingelheim, AstronauTx, and Cephagenix. Based in Copenhagen, Saniona is listed on Nasdaq Stockholm Main Market.

For more information, visit www.saniona.com.

Attachments

Saniona highlights Acadia Pharmaceuticals' upcoming R&D Day